Human cytomegalovirus (HCMV) is a herpesvirus that infects~ 60% of adults in developed
countries and more than 90% in developing countries. Usually, it is controlled by a vigorous …

Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common
complications affecting solid organ transplant recipients, conveying higher risks of …

Background Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …

Background Cytomegalovirus (CMV) infection remains a common complication after
allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the …

Cytomegalovirus is one of the most important infections to occur after allogeneic
haematopoietic stem cell transplantation (HSCT), and an increasing number of reports …

Cytomegalovirus (CMV) infection and disease are important causes of morbidity and
mortality in transplant recipients. For the purpose of developing consistent reporting of CMV …

Single-center studies have reported an association between early (before day 100)
cytomegalovirus (CMV) reactivation and decreased incidence of relapse for acute myeloid …

Human cytomegalovirus (HCMV) is a recognized cause of disease in the fetus, the allograft
recipient and AIDS patients. More recently, it has been recognized as a pathogen for those …

Background Although cytomegalovirus viral load is commonly used to guide pre-emptive
therapy in the post-transplantation setting, few data are available correlating viraemia with …

Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ
transplantation, resulting in significant morbidity, graft loss, and adverse outcomes …